Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants

Takeshi Akiyoshi, Takashi Saito, Saori Murase, Mitsue Miyazaki, Norie Murayama, Hiroshi Yamazaki, F. Peter Guengerich, Katsunori Nakamura, Koujirou Yamamoto, Hisakazu Ohtani

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

CYP3A4, an important drug-metabolizing enzyme, is known to have genetic variants. We have previously reported that CYP3A4 variants such as CYP3A4.2, 7, 16, and 18 show different enzymatic kinetics from CYP3A4.1 (wild type). In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions. The inhibitory profiles of ITCZ and CMD on the metabolism of testosterone (TST) were analyzed by using recombinant CYP3A4 variants. The genetic variation of CYP3A4 significantly affected the inhibition profiles of the two inhibitors. In CYP3A4.7, the Ki value for ITCZ was 2.4-fold higher than that for the wild-type enzyme, whereas the Ki value for CMD was 0.64-fold lower. In CYP3A4.16, the Ki value for ITCZ was 0.54-fold lower than that for wild-type CYP3A4, whereas the Ki value for CMD was 3.2-fold higher. The influence of other genetic variations also differed between the two inhibitors. Docking simulations could explain the changes in the Ki values, based on the accessibility of TST and inhibitors to the heme moiety of the CYP3A4 molecule. In conclusion, the inhibitory effects of an inhibitor differ among CYP3A4 variants, suggesting that the genetic variation of CYP3A4 may contribute, at least in part, to interindividual differences in drug interactions mediated by CYP3A4 inhibition, and the pattern of the influences of genetic variation differs among inhibitors as well as substrates.

Original languageEnglish
Pages (from-to)724-728
Number of pages5
JournalDrug Metabolism and Disposition
Volume39
Issue number4
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Cytochrome P-450 CYP3A
Itraconazole
Cimetidine
Drug Interactions
Testosterone
Enzymes
Heme

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. / Akiyoshi, Takeshi; Saito, Takashi; Murase, Saori; Miyazaki, Mitsue; Murayama, Norie; Yamazaki, Hiroshi; Guengerich, F. Peter; Nakamura, Katsunori; Yamamoto, Koujirou; Ohtani, Hisakazu.

In: Drug Metabolism and Disposition, Vol. 39, No. 4, 04.2011, p. 724-728.

Research output: Contribution to journalArticle

Akiyoshi, T, Saito, T, Murase, S, Miyazaki, M, Murayama, N, Yamazaki, H, Guengerich, FP, Nakamura, K, Yamamoto, K & Ohtani, H 2011, 'Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants', Drug Metabolism and Disposition, vol. 39, no. 4, pp. 724-728. https://doi.org/10.1124/dmd.110.036780
Akiyoshi, Takeshi ; Saito, Takashi ; Murase, Saori ; Miyazaki, Mitsue ; Murayama, Norie ; Yamazaki, Hiroshi ; Guengerich, F. Peter ; Nakamura, Katsunori ; Yamamoto, Koujirou ; Ohtani, Hisakazu. / Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. In: Drug Metabolism and Disposition. 2011 ; Vol. 39, No. 4. pp. 724-728.
@article{b678e8eff33d4b17946c0c59985b56e2,
title = "Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants",
abstract = "CYP3A4, an important drug-metabolizing enzyme, is known to have genetic variants. We have previously reported that CYP3A4 variants such as CYP3A4.2, 7, 16, and 18 show different enzymatic kinetics from CYP3A4.1 (wild type). In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions. The inhibitory profiles of ITCZ and CMD on the metabolism of testosterone (TST) were analyzed by using recombinant CYP3A4 variants. The genetic variation of CYP3A4 significantly affected the inhibition profiles of the two inhibitors. In CYP3A4.7, the Ki value for ITCZ was 2.4-fold higher than that for the wild-type enzyme, whereas the Ki value for CMD was 0.64-fold lower. In CYP3A4.16, the Ki value for ITCZ was 0.54-fold lower than that for wild-type CYP3A4, whereas the Ki value for CMD was 3.2-fold higher. The influence of other genetic variations also differed between the two inhibitors. Docking simulations could explain the changes in the Ki values, based on the accessibility of TST and inhibitors to the heme moiety of the CYP3A4 molecule. In conclusion, the inhibitory effects of an inhibitor differ among CYP3A4 variants, suggesting that the genetic variation of CYP3A4 may contribute, at least in part, to interindividual differences in drug interactions mediated by CYP3A4 inhibition, and the pattern of the influences of genetic variation differs among inhibitors as well as substrates.",
author = "Takeshi Akiyoshi and Takashi Saito and Saori Murase and Mitsue Miyazaki and Norie Murayama and Hiroshi Yamazaki and Guengerich, {F. Peter} and Katsunori Nakamura and Koujirou Yamamoto and Hisakazu Ohtani",
year = "2011",
month = "4",
doi = "10.1124/dmd.110.036780",
language = "English",
volume = "39",
pages = "724--728",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants

AU - Akiyoshi, Takeshi

AU - Saito, Takashi

AU - Murase, Saori

AU - Miyazaki, Mitsue

AU - Murayama, Norie

AU - Yamazaki, Hiroshi

AU - Guengerich, F. Peter

AU - Nakamura, Katsunori

AU - Yamamoto, Koujirou

AU - Ohtani, Hisakazu

PY - 2011/4

Y1 - 2011/4

N2 - CYP3A4, an important drug-metabolizing enzyme, is known to have genetic variants. We have previously reported that CYP3A4 variants such as CYP3A4.2, 7, 16, and 18 show different enzymatic kinetics from CYP3A4.1 (wild type). In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions. The inhibitory profiles of ITCZ and CMD on the metabolism of testosterone (TST) were analyzed by using recombinant CYP3A4 variants. The genetic variation of CYP3A4 significantly affected the inhibition profiles of the two inhibitors. In CYP3A4.7, the Ki value for ITCZ was 2.4-fold higher than that for the wild-type enzyme, whereas the Ki value for CMD was 0.64-fold lower. In CYP3A4.16, the Ki value for ITCZ was 0.54-fold lower than that for wild-type CYP3A4, whereas the Ki value for CMD was 3.2-fold higher. The influence of other genetic variations also differed between the two inhibitors. Docking simulations could explain the changes in the Ki values, based on the accessibility of TST and inhibitors to the heme moiety of the CYP3A4 molecule. In conclusion, the inhibitory effects of an inhibitor differ among CYP3A4 variants, suggesting that the genetic variation of CYP3A4 may contribute, at least in part, to interindividual differences in drug interactions mediated by CYP3A4 inhibition, and the pattern of the influences of genetic variation differs among inhibitors as well as substrates.

AB - CYP3A4, an important drug-metabolizing enzyme, is known to have genetic variants. We have previously reported that CYP3A4 variants such as CYP3A4.2, 7, 16, and 18 show different enzymatic kinetics from CYP3A4.1 (wild type). In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions. The inhibitory profiles of ITCZ and CMD on the metabolism of testosterone (TST) were analyzed by using recombinant CYP3A4 variants. The genetic variation of CYP3A4 significantly affected the inhibition profiles of the two inhibitors. In CYP3A4.7, the Ki value for ITCZ was 2.4-fold higher than that for the wild-type enzyme, whereas the Ki value for CMD was 0.64-fold lower. In CYP3A4.16, the Ki value for ITCZ was 0.54-fold lower than that for wild-type CYP3A4, whereas the Ki value for CMD was 3.2-fold higher. The influence of other genetic variations also differed between the two inhibitors. Docking simulations could explain the changes in the Ki values, based on the accessibility of TST and inhibitors to the heme moiety of the CYP3A4 molecule. In conclusion, the inhibitory effects of an inhibitor differ among CYP3A4 variants, suggesting that the genetic variation of CYP3A4 may contribute, at least in part, to interindividual differences in drug interactions mediated by CYP3A4 inhibition, and the pattern of the influences of genetic variation differs among inhibitors as well as substrates.

UR - http://www.scopus.com/inward/record.url?scp=79952848727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952848727&partnerID=8YFLogxK

U2 - 10.1124/dmd.110.036780

DO - 10.1124/dmd.110.036780

M3 - Article

C2 - 21212239

AN - SCOPUS:79952848727

VL - 39

SP - 724

EP - 728

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 4

ER -